Market is well and truly asleep on this one Gavin.Feels like...

First 2 Last

Share
Profile

Follow
FreedomInvestor

4,080 Posts.

708

19/08/22

10:43

Post #: 63207595
Share

Originally posted by gavncath: ↑

Hi PTX-ers,

You'll see from my previous posts, I'm sold on PTX. I am overweight in my portfolio on PTX... but comfortable in that position.

I'm excited by the science, I remain enthusiastic in what PTX will likely deliver to the world in cancer cures in the medium to long term.

I totally love yesterdays announcement with plans to utilise mechanism rather than viruses to have the omnicar DNA transferred into immune cells... I understand that the current viral transfer process will transfer DNA to anything between 20 and 70% of the available cells... The process is inefficient, very user dependent, slow and therefore expensive and not routinely reproducible. Assuming this deal is successful, we own the IP, we have standardised product and reduce costs... but at no expense to PTX... the dream!

Congrats to Steven, the board and the team.

The most important point here... our SP is waaay too cheap. Assuming success, PTX tech is scalable in the extreme, will be disruptive in the cancer care market and frankly is a sensational takeover target for bigger players... my concern on PTX... Do holders really understand the potential value here?? I just hope longer term holders 'get' this and don't fold on a mere 100x return!

Gav

Expand

Market is well and truly asleep on this one Gavin.

Feels like early days PNV (but better imo)

PTX Price at posting: 21.5¢ Sentiment: Buy Disclosure: Held
19 Upvote

2 Great analysis

Reply

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

There are more pages in this discussion • 13 more messages in this thread...

First 2 Last

Add PTX (ASX) to my watchlist

(20min delay)
Last 4.7¢		Change 0.002(4.44%)		Mkt cap ! $37.85M

Open	High	Low	Value	Volume
4.6¢	4.9¢	4.6¢	$32.17K	677.4K

Buyers (Bids)

No.	Vol.	Price($)
1	25682	4.7¢

Sellers (Offers)

Price($)	Vol.	No.
4.8¢	221710	2

View Market Depth

No.	Vol.	Price($)
1	25682	0.047
1	170999	0.046
2	25000	0.045
2	65454	0.044
1	70000	0.043

Price($)	Vol.	No.
0.048	221710	2
0.049	228740	4
0.050	236935	5
0.051	19607	1
0.052	60000	1

Last trade - 14.32pm 07/10/2024 (20 minute delay)

PTX (ASX) Chart

Market is well and truly asleep on this one Gavin.Feels like...

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Market is well and truly asleep on this one Gavin.Feels like...

Top Stories

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News